GLAXO v. NOVOPHARM ZANTAC "POTENTIAL" INFRINGEMENT ARGUMENT QUESTIONED BY FEDERAL APPEALS COURT; ABBOTT HYTRIN APPEAL RULING EXPECTED SHORTLY
Executive Summary
Glaxo's argument that Novopharm's ANDA for generic ranitidine Form 1 has the potential to include Form 2 ranitidine in violation of Glaxo's patent on Zantac (ranitidine Form 2) was questioned by a three-judge D.C. federal appeals court Jan. 7.